Stanley Druckenmiller’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Stanley Druckenmiller’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,095,200	Closed	-$123M	–	81
2020 Q2	$123M	Buy	+1,095,200	New	+$108M	3.75%	9

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Stanley Druckenmiller's XBI Position: Q3 2020 in Review

Stanley Druckenmiller sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2020, closing a stake of 1,095,200 shares — an estimated $123M sold.

Stanley Druckenmiller first reported a position in XBI in Q2 2020 and held it in 1 quarter. The position peaked at $123M in Q2 2020. 554 funds tracked by Wall St. Rank hold XBI as of Q3 2020.

Stanley Druckenmiller reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2020 after selling out during the quarter.
Stanley Druckenmiller sold 1,095,200 State Street SPDR S&P Biotech ETF shares in Q3 2020, an estimated $123M.
Stanley Druckenmiller first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and held it in 1 quarter.
Stanley Druckenmiller's State Street SPDR S&P Biotech ETF position peaked at $123M in Q2 2020.
554 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2020.

Based on Duquesne Family Office's 13F filing for Q3 2020, filed 16 Nov 2020.